Entrada Therapeutics (TRDA) Accumulated Depreciation (2020 - 2021)
Entrada Therapeutics (TRDA) recorded quarterly Accumulated Depreciation of $1.4 million in Q4 2021, up 34.6% quarter-over-quarter from $1.1 million in Q3 2021, and up 275.6% on a YoY basis from $377000.0 in Q4 2020.
Entrada Therapeutics (TRDA) Accumulated Depreciation (2020 - 2021) Analysis & Trends
Entrada Therapeutics' Accumulated Depreciation history runs 2 years deep, the most recent figure standing at $1.4 million for Q4 2021.
- In Q4 2021, Accumulated Depreciation rose 275.6% year-over-year to $1.4 million; the TTM figure through Dec 2021 stood at $1.4 million (up 275.6% YoY), while the FY2021 annual figure was $1.4 million, up 275.6% from the prior year.
- Accumulated Depreciation was $1.4 million for Q4 2021 at Entrada Therapeutics, up from $1.1 million in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $1.4 million in Q4 2021 to a low of $377000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Entrada Therapeutics | 295.36 Mn | 295.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.42 Mn |
| Sep 30, 2021 | 1.05 Mn |
| Dec 31, 2020 | 377,000.00 |